Hypertriglyceridemia — current status of the problem. Part II: primary and secondary hypertriglyceridemias, treatment options
Russian Journal of Cardiology,
Год журнала:
2025,
Номер
30(2), С. 6240 - 6240
Опубликована: Март 15, 2025
Hypertriglyceridemias
are
a
heterogeneous
group
of
pathologies
differing
in
the
mechanisms
triglyceride-rich
lipoprotein
increase,
composition
lipoproteins
and
related
risks.
This
review
article
presents
information
on
profile
pathogenesis
various
primary
secondary
hypertriglyceridemias,
as
well
describes
current
potential
genetic
diagnostics,
drug
non-drug
correction.
Язык: Английский
Baicalin alleviates lipid accumulation in adipocytes via inducing metabolic reprogramming and targeting Adenosine A1 receptor
Toxicon,
Год журнала:
2025,
Номер
unknown, С. 108339 - 108339
Опубликована: Апрель 1, 2025
Язык: Английский
Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia
Cardiology and Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 5, 2025
In
dyslipidemia
associated
with
type
2
diabetes
(T2DM),
elevated
triglycerides
(TG),
increased
low-density
lipoprotein
cholesterol
(LDL-C),
and
decreased
high-density
(HDL-C)
levels
are
commonly
found,
resulting
in
a
high
prevalence
of
mixed
among
patients
T2DM.
Therefore,
the
combination
therapy
atorvastatin/fenofibrate
may
be
useful
for
simplifying
pharmacological
regimens,
enhancing
adherence,
requiring
fewer
doses
each
drug
to
achieve
target,
which
decreases
number
adverse
events.
We
conducted
randomized
multicenter,
double-blind
clinical
trial
T2DM
evaluate
magnitude
change
lipid
profile
fixed-dose
(FDC)
group
atorvastatin
20
mg/fenofibrate
160
mg
(G_FDC)
versus
monotherapy
(G_M),
both
oral
route,
one
tablet
every
24
h.
The
at
4
months
was
compared
within
between
groups
using
analysis
variance
(ANOVA)
test.
A
p
value
≤
0.05
considered
statistically
significant.
total
76
were
included
(38
per
group),
an
age
56.7
±
10.2
years,
56.6%
women.
values
G_FDC
vs.
G_M
as
follow:
TG
mg/dL
(-144.3
-64.0,
=
0.004),
percentage
(%C)
(-47.9
-33.1,
0.007);
LDL-C
(-50.5
-51.7,
0.784),
%C
(-42.5
-45.6,
0.899).
who
achieved
targets
(TG)
56.7%
43.8%
(p
0.309),
while
LDL-C,
it
73.3%
78.1%
0.660).
Finally,
predictive
cardiovascular
risk
indices
(∆
change)
showed
TG/HDL
index
-3.9
4.6
-1.5
2.9
0.015)
Tg/glucose
-0.7
0.5
-0.3
0.4
0.003).
FDC
greater
reduction
than
alone.
No
differences
events
observed
groups.
ClinicalTrials.gov
No.
NCT04882293,
registration
date:
February
28,
2022.
Язык: Английский
Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025).
Eurasian heart journal,
Год журнала:
2025,
Номер
2, С. 6 - 34
Опубликована: Июнь 2, 2025
Cardiovascular
diseases
are
one
of
the
main
causes
mortality
and
disability
among
population
member
countries
Eurasian
Association
Cardiology,
which
is
directly
related
to
high
prevalence
risk
factors
for
atherosclerosis,
dyslipidemia
plays
a
leading
role.
The
previous
version
Recommendations
Diagnosis
correction
lipid
metabolism
disorders
prevention
treatment
atherosclerosis
was
presented
in
2020.
Over
past
5
years,
approaches
stratification,
diagnosis
subclinical
using
various
classes
lipid-lowering
drugs
have
changed
significantly.
Among
initial
updates,
proposals
should
be
highlighted
determining
blood
level
each
adult
or
upon
reaching
age
18,
SCORE
and/or
SCORE2
scales
stratify
cardiovascular
risk,
non-invasive
imaging
techniques
assess
atherosclerosis.
In
sections
devoted
therapy,
fixed
combinations
drugs,
inclisiran,
bempedoic
acid
presented.
section
on
prevalence,
significance
hypertriglyceridemia,
as
well
extracorporeal
hemocorrection,
has
been
expanded.
A
chapter
lipoprotein(a)
introduced.
Sections
cerebrovascular
diseases,
heart
transplantation
HIV
infection
These
recommendations
will
useful
phisicians
all
specialties
effective
management
their
patients.
Язык: Английский
The Prevention Opportunities of Retinopathy in Diabetic Patients - the Position Paper endorsed by the Polish Lipid Association.
Archives of Medical Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 13, 2024
CVD
prevention
does
not
only
mean
effective
fight
against
the
existing
cardiovascular
risk
factors,
but
also
their
complications,
including
micro-
and
macrovascular
ones.
In
relation
to
obesity,
prediabetes
diabetes,
we
recognize
a
number
of
potential
dangerous
non-cardiovascular
such
as
neuropathy,
nephropathy
retinopathy.
The
latter’s
prevalence
is
even
30-40%
may
appear
in
many
15%
patients
with
prediabetes.
Not
treated
well
might
result
necessity
eye
surgery
or
vision
loss.
Fenofibrate
has
had
long
history
evidence
suggesting
preventive
role
primary
especially
secondary
retinopathy,
what
been
being
investigated
since
FIELD
trial
19
years
ago.
this
Position
Paper
have
reviewed
current
stage
knowledge
on
possible
mechanisms,
by
which
fenofibrate
contribute
retinopathy
prevention,
available
data
safety
efficacy,
finally
recommend
administrating
diabetic
complication.
Язык: Английский